- Home
- DCTH vs CSTL Comparison
DCTH vs CSTL Comparison
Compare DCTH & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- CSTL
- Stock Information
- Founded
- DCTH 1988
- CSTL 2007
- Country
- DCTH United States
- CSTL United States
- Employees
- DCTH N/A
- CSTL N/A
- Industry
- DCTH Medical/Dental Instruments
- CSTL Medical Specialities
- Sector
- DCTH Health Care
- CSTL Health Care
- Exchange
- DCTH Nasdaq
- CSTL Nasdaq
- Market Cap
- DCTH 518.0M
- CSTL 568.2M
- IPO Year
- DCTH N/A
- CSTL 2019
- Fundamental
- Price
- DCTH $11.87
- CSTL $21.98
- Analyst Decision
- DCTH Strong Buy
- CSTL Strong Buy
- Analyst Count
- DCTH 4
- CSTL 6
- Target Price
- DCTH $22.75
- CSTL $40.00
- AVG Volume (30 Days)
- DCTH 458.0K
- CSTL 333.7K
- Earning Date
- DCTH 05-13-2025
- CSTL 05-05-2025
- Dividend Yield
- DCTH N/A
- CSTL N/A
- EPS Growth
- DCTH N/A
- CSTL N/A
- EPS
- DCTH N/A
- CSTL 0.62
- Revenue
- DCTH $37,205,000.00
- CSTL $332,069,000.00
- Revenue This Year
- DCTH $128.78
- CSTL N/A
- Revenue Next Year
- DCTH $54.07
- CSTL $3.34
- P/E Ratio
- DCTH N/A
- CSTL $35.23
- Revenue Growth
- DCTH 1701.69
- CSTL 51.09
- 52 Week Low
- DCTH $5.04
- CSTL $16.97
- 52 Week High
- DCTH $16.97
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- DCTH 47.65
- CSTL 58.49
- Support Level
- DCTH $11.05
- CSTL $18.03
- Resistance Level
- DCTH $11.84
- CSTL $21.81
- Average True Range (ATR)
- DCTH 0.97
- CSTL 1.25
- MACD
- DCTH 0.09
- CSTL 0.43
- Stochastic Oscillator
- DCTH 57.89
- CSTL 97.61
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.